BRCA1 carriers commonly develop aggressive cancers (triple-negative with high nuclear grade), with peak incidence in the 41–50 age-group, while BRCA2 carriers commonly develop cancers that are less aggressive (estrogen receptor (ER)-positive) with peak incidence in the 51–60 age-group [3,4]. This evidence concerns the gene BRCA2 and cancer.